BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

EnVivo Pharmaceuticals, Inc. Announces Neuropharmacology Publication, Confirms Novel Mechanism of Action of Lead Program EVP-6124


12/13/2011 7:16:19 AM

WATERTOWN, Mass.--(BUSINESS WIRE)--EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today announced data published in the peer-reviewed journal Neuropharmacology confirming the novel mechanism of action of its lead program EVP-6124. EnVivo has demonstrated that EVP-6124 is a potent and highly selective agonist of alpha-7 neuronal nicotinic acetylcholine receptors (nAChRs) in the brain and that treatment with EVP-6124, both alone and in combination with donepezil, restored memory loss and improved memory function in preclinical models. These findings further support the company’s clinical development strategy for EVP-6124 as a long-term treatment to restore and improve cognitive function with sustained effect in schizophrenia and Alzheimer’s disease.

Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->